Ernest Waaser has been named the CEO of NuSil Technology LLC. Waaser assumes the role from Dick Compton, who is retiring but will continue to serve as chairman of the NuSil Board of Directors.
Waaser brings over 30 years of experience from numerous public and privately-held healthcare companies to his new role. Prior to NuSil, Waaser was an operating partner at Linden Capital Partners and previous to that served as CEO of Systagenix Wound Management, a private equity-backed spinout of Johnson & Johnson's advanced wound care unit.
Waaser spent his early career in various roles with DuPont's chemical, industrial and imaging businesses. In the nearly two decades following his career at DuPont, Waaser was president of Teleflex Medical, CEO of Hill-Rom, and COO of Sterling Diagnostic Imaging, a leveraged buy-out of DuPont's medical imaging assets. Waaser previously served on the board of AdvaMed and on the advisory board of Xavier University Department of Health Administration. He holds a bachelor of science in nuclear engineering from Mississippi State University and a master of engineering from the University of South Carolina.
"With his proven track record of growing global Medtech businesses, we believe he is absolutely the right person to lead NuSil through its next phase of growth and expansion. Our ability to recruit this kind of talent speaks to the outstanding job that Dick Compton and the management team have done in building an exciting, growth oriented environment at NuSil. Dick is a true icon in the specialty silicone industry, and we are pleased that he will continue as Chairman of the Board," noted Matt Holt, a member of the board of directors and managing director at New Mountain Capital.